-
1.发明授权公开(公告)号：US07615651B2
公开(公告)日：2009-11-10
申请号：US11938821
申请日：2007-11-13
IPC分类号： C07C211/00
CPC分类号： C07C237/30 , C07C237/32 , C07C237/38 , C07C255/58 , C07C311/08 , C07C2601/02 , C07C2601/08 , C07C2602/08 , C07C2602/10 , C07D209/44 , C07D213/24 , C07D231/12 , C07D235/26 , C07D249/08 , C07D277/28 , C07D295/20 , C07D295/205 , C07D307/00 , C07D307/14 , C07D307/82 , C07D311/58 , C07D317/32
摘要： Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R, R1, R2a, R2b, R3, R4, V, R6, R7, R8, R9, W and X are described herein.
摘要翻译： 在本文中描述了在mu，κ和/或δ阿片受体上作为拮抗剂并因此可用于治疗受益于动物中的这种拮抗作用的疾病，病症和/或病症的式（I）化合物。 其中R，R 1，R 2a，R 2b，R 3，R 4，V，R 6，R 7，R 8，R 9，W和X在本文中描述。
-
2.发明申请公开(公告)号：US20080167371A1
公开(公告)日：2008-07-10
申请号：US11938821
申请日：2007-11-13
IPC分类号： A61K31/35 , A61K31/165 , C07C237/44
CPC分类号： C07C237/30 , C07C237/32 , C07C237/38 , C07C255/58 , C07C311/08 , C07C2601/02 , C07C2601/08 , C07C2602/08 , C07C2602/10 , C07D209/44 , C07D213/24 , C07D231/12 , C07D235/26 , C07D249/08 , C07D277/28 , C07D295/20 , C07D295/205 , C07D307/00 , C07D307/14 , C07D307/82 , C07D311/58 , C07D317/32
摘要： Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R, R1, R2a, R2b, R3, R4, V, R6, R7, R8, R9, W and X are described herein.
摘要翻译： 在本文中描述了在mu，κ和/或δ阿片受体上作为拮抗剂并因此可用于治疗受益于动物中的这种拮抗作用的疾病，病症和/或病症的式（I）化合物。 其中R，R 1，R 2a，R 2b，R 3，R 4， 描述了SUP>，V，R 6，R 7，R 8，R 9，W和X 这里。
-
3.发明授权公开(公告)号：US07235259B2
公开(公告)日：2007-06-26
申请号：US10066091
申请日：2002-02-01
申请人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
CPC分类号： A61K31/4196 , A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K31/41 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
摘要翻译： 药物组合物包含胆固醇酯转移蛋白抑制剂和浓度增强聚合物的固体无定形分散体。
-
公开(公告)号：US07115279B2
公开(公告)日：2006-10-03
申请号：US09918127
申请日：2001-07-30
申请人： William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
CPC分类号： A61K9/1652 , A61K9/146 , A61K9/1635 , A61K31/4196 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
-
公开(公告)号：US06197786B1
公开(公告)日：2001-03-06
申请号：US09391152
申请日：1999-09-07
IPC分类号： A61K3147
CPC分类号： C07D409/04 , A61K31/47 , C07D215/42 , C07D215/48 , C07D221/16 , C07D409/12
摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译： 胆固醇酯转移蛋白抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。
-
6.发明授权
公开(公告)号：US6147089A
公开(公告)日：2000-11-14
申请号：US390738
申请日：1999-09-07
IPC分类号： A61K31/4706 , A61K31/473 , A61K31/4741 , A61K31/4745 , A61P3/06 , A61P9/00 , A61P9/10 , A61P43/00 , C07D215/42 , C07D215/58 , C07D221/10 , C07D221/16 , C07D471/04 , C07D491/04 , C07D491/048 , C07D491/056 , C07D495/04 , C07D513/04 , A61K31/47 , C07D215/38
CPC分类号： C07D471/04 , C07D215/42 , C07D221/16 , C07D491/04 , C07D495/04 , Y02P20/55
摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译： 胆固醇酯转移蛋白抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。
-
公开(公告)号：US6140343A
公开(公告)日：2000-10-31
申请号：US391313
申请日：1999-09-07
IPC分类号： C07D215/16 , A61K20060101 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/473 , A61K45/00 , A61P3/04 , A61P3/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P31/00 , C07D20060101 , C07D215/00 , C07D215/42 , C07D215/46 , C07D221/06 , C07D221/16 , C07D413/12 , C07D417/12 , C07D215/38
CPC分类号： C07D413/12 , C07D215/42 , C07D215/46 , C07D221/16 , C07D417/12
摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
-
公开(公告)号：US20130123230A1
公开(公告)日：2013-05-16
申请号：US13670852
申请日：2012-11-07
申请人： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
发明人： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC分类号： C07D239/56 , C07D401/04 , C07D405/10 , C07D403/10 , C07D487/04 , C07D409/10 , C07D417/10 , C07D401/06 , C07D403/06 , C07D413/06 , A61K31/5377 , C07D405/04 , C07D403/04 , C07D409/04 , C07D401/10 , C07D403/12 , A61K31/352 , A61K45/06 , A61K31/513
CPC分类号： C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号：US07618996B2
公开(公告)日：2009-11-17
申请号：US11852358
申请日：2007-09-10
IPC分类号： A61K31/35 , A61K31/165 , C07C237/00 , C07D315/00
CPC分类号： C07D307/14 , C07C235/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D213/38 , C07D309/04
摘要： Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R1, R2, R3, R4, R5, and R6 are described herein.
摘要翻译： 在本文中描述了在mu，κ和/或δ阿片受体上作为拮抗剂并因此可用于治疗受益于动物中的这种拮抗作用的疾病，病症和/或病症的式（I）化合物。 其中R1，R2，R3，R4，R5和R6如本文所述。
-
公开(公告)号：US06489478B1
公开(公告)日：2002-12-03
申请号：US09671221
申请日：2000-09-27
IPC分类号： A61K3147
CPC分类号： C07D413/12 , C07D215/42 , C07D215/46 , C07D221/16 , C07D417/12
摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译： 胆固醇酯转移蛋白抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.041 秒)
